Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients

Journal of Lipid Research

Volumn 43, Issue 8, 2002, Pages 1170-1180

  Morrisett, Joel D ^a   Abdel Fattah, Ghada ^a   Hoogeveen, Ron ^a   Mitchell, Eddie ^a   Ballantyne, Christie M ^a   Pownall, Henry J ^a   Opekun, Antone R ^a   Jaffe, Jonathon S ^c   Oppermann, Suzanne ^b   Kahan, Barry D ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c WYETH AYERST RESEARCH   (United States)

Author keywords

Cholesterol; Rapamycin; Triglyceride

Indexed keywords

APOLIPOPROTEIN B100; CYCLOSPORIN A; FATTY ACID; INSULIN; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PALMITIC ACID; PREDNISONE; RAPAMMUNE; RAPAMYCIN; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; ENZYME ACTIVITY; FATTY ACID METABOLISM; FEMALE; GRAFT REJECTION; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; KIDNEY TRANSPLANTATION; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0036691215     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: 10.1194/jlr.m100392-jlr200     Document Type: Article

References (36)

1. Efficacy of sirolimus compared with azathioprine for reduction of acute allograft rejection: A randomized multicenter study
2. Sirolimus a potent new immunosuppressive agent for liver transplantation
3. Pediatric utilization of rapamycin for severe cardiac allograft rejection
4. Rapamycin inhibits vascular smooth muscle cell migration
5. Neointimal formation after balloon-induced vascular injury in Yucatan minipigs is reduced by oral rapamycin
6. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle
7. A mammalian protein targeted by G1-arresting rapamycin-receptor complex
8. EIF4E activity is regulated at multiple levels
9. Phosphorylation of the translational repressor PHAS-1 by the mammalian target of rapamycin
10. RAFT-1 phosphorylation of the translational regulator p70S6 kinase and 4EBP-1
11. Regulation of the rapamycin and FKBP-target 1/mammalian target of rapamycin and cap-dependent initiation of translation by the c-abl protein-tyrosine kinase
12. Hypertriglyceridemia in renal transplant recipients treated with sirolimus
13. Hyperlipidemia in renal transplant recipients treated with Sirolimus (Rapamycin)
14. Effect of rapamycin on the metabolism of Apo B-100 containing lipoproteins in renal transplant patients
15. Routine clinical monitoring of sirolimus (rapamycin) whole-blood concentrations by HPLC with ultraviolet detection
16. Reagents for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency
17. Reagent for the enzymatic determination of serum total triglyceride with improved lipolytic efficacy
18. Dextran Sulfate-Mg2+ precipitation procedure for the quantification of high density-lipoprotein cholesterol
19. Restriction isotyping of the human apolipoprotein E by gene amplification and cleavage with Hhal
20. Separation of plasma lipoproteins by density gradient ultracentrifugation
21. Thin layer chromatography of lipids
22. Isotopic determination of organic keto acid pentafluorobenzyl esters in biological fluids by negative chemical ionization gas chromatography/mass spectrometry
23. Lipoprotein lipase: Some effects of activator proteins
24. Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein CIII
25. Apolipoprotein B metabolism in subjects with deficiency of apo CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride rich lipoproteins by lipoprotein lipase in vivo
26. The side effect profile of sirolimus: A phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients
27. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal trasnplantation
28. Rapamycin: Personal algorithms for use based on 250 treated allograft recipients
29. The Rapamune Global Study Group: A randomized, placebo-controlled trial of rapammune in primary renal allograft recipients
30. Therapeutic drug monitoring of sirolimus: Correlations with efficacy and toxicity
31. Immunological assays of apolipoproteins A-II, A-IV, C-I, C-II, C-III in plasma
32. Hyperlipidemia and post-heparin lipase activities in renal transplant recipients treated with sirolimus or cyclosporin A
33. Effect of rapamycin on free fatty acid metabolism in renal transplant patients
34. Model for measuring absolute rates of hepatic de novo lipogenesis and reesterification of free fatty acids